News articles about Opexa Therapeutics (NASDAQ:ACER) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Opexa Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.3797476772452 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Separately, ValuEngine raised shares of Opexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd.

WARNING: “Opexa Therapeutics (ACER) Receives Daily Coverage Optimism Rating of 0.11” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://theolympiareport.com/2017/11/01/opexa-therapeutics-acer-receives-daily-coverage-optimism-rating-of-0-11.html.

About Opexa Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.